<a href="https://laohu8.com/S/VSTM">Verastem</a> Oncology Secures FDA Approval for Avutometinib Plus Defactinib in KRAS-Mutated Low-Grade Serous Ovarian Cancer
Verastem Oncology has announced a significant milestone with the recent FDA approval of the combination therapy avutometinib plus defactinib for treating KRAS-mutated recurrent low-grade serous ovarian cancer. This approval is grounded in the promising results from the FRAME study, which demonstrated significant clinical activity and safety of this combination. The study showed a noteworthy objective response rate and progression-free survival, particularly in patients with KRAS mutations. This approval supports Verastem's commitment to advancing treatments for RAS/MAPK pathway-driven cancers, and the therapy is now being tested in other solid tumors, including in a global Phase 3 trial for first-line metastatic pancreatic cancer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250630352590) on June 30, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。